Efficacy Study on Symptomatic Control of Patient With Knee Osteoarthritis Between 0.0125% of Capsaicin to Placebo
NCT ID: NCT00471055
Last Updated: 2008-07-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
100 participants
INTERVENTIONAL
2007-06-30
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A
Capsaicin and placebo controlled,Cross-over design study
0.0125% Capsaicin gel "CAPSIKA gel"
B
Capsaicin and placebo controlled,Cross-over design study
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
0.0125% Capsaicin gel "CAPSIKA gel"
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Subjects who are capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
2. Ambulatory nom pregnant females and males 40-\<80 years of age.
3. Subjects who withdraw pain medication or nutritional supplements for symptom relief for knee OA for a total of at least 15 days before screening visit 0.
4. Pain at or below 80 mm on a 100 mm VAS in the index knee.
5. A documented diagnosis of OA of the knee, or meeting American College of Rheumatology (ACR) clinical criteria for classification of idiopathic (primary) OA for at least 6 months prior to screening. If OA is presented in both knees the investigator will identify which knee will be X-rayed for study entry, with preference for the knee with more severe pain (\<80mm VAS).
6. Has documented radiographic evidence of OA of the knee from the screening Visit radiograph of grade 2 or 3 according to Kellgren and Lawrence Radiographic Grading.
7. Subjects with baseline minimum joint space width in the medial compartment of the index knee of \> 1.5 mm at Baseline, measured from radiographs using the MTP view.
8. Subjects with baseline minimum joint space width in the lateral compartment of the index knee of \> 2.5 mm at Baseline, measured from radiographs using the MTP view.
9. Subject is able to understand and complete pain/function, global arthritis evaluation, and health outcome assessment.
Exclusion Criteria
1. Subjects with history of hypersensitivity to capsaicin.
2. Subjects with skin lesion at the index knee.
3. A history of lower extremity surgery within 6 months prior to screening V0.
4. Significant prior injury to the index knee within 12 months prior to screening V0.
5. Disease of the spine or other lower extremity joints of sufficient degree to affect the index knee.
6. Treatment with other drugs potentially affecting bone or cartilage metabolism as described below:
* chronic systematic corticosteroids
* hyaluronan injection into the index knee with in the previous 6 months.
* Diacerin treatment within the last 12 months.
40 Years
80 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bangkok Laboratories and Cosmetics
UNKNOWN
Khon Kaen University
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
weerachai Kosuwon, M.D
Role: PRINCIPAL_INVESTIGATOR
Department of Orthopedics, Faculty of Medicine, Khon kaen University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Weerachai Kosuwon
Khon Kaen University, Changwat Khon Kaen, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Khonkaen-ortho 1
Identifier Type: -
Identifier Source: org_study_id